Immunogen Inc. (IMGN) PT Raised to $4 at SVB Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Immunogen Inc. (IMGN) PT Raised to $4 at SVB Leerink
December 17, 2019 11:13 AM EST
H.C. Wainwright analyst Debjit Chattopadhyay raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $9.00 (from $5.00) while maintaining a Buy rating.
compelling regulatory advance that they did not anticipate....
More
December 17, 2019 9:35 AM EST
Today's Pre-Open Movers
Proteostasis Therapeutics, Inc. (NASDAQ: PTI) 42.5% LOWER; announced positive topline results from the Company's global, multicenter, randomized, placebo-controlled, 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heterozygous CF subjects 18 years of age and older.
MEI Pharma, Inc. (NASDAQ: MEIP) 22.5% LOWER; announced today that it has priced the underwritten public offering of 28,125,000 shares of its common stock at $1.60 per share for total gross... More
December 17, 2019 6:45 AM EST
Immunogen (NASDAQ: IMGN) climbed 37% pre-open after announcing that FDA has advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval for mirvetuximab soravtansine.
...
More
December 17, 2019 6:31 AM EST
ImmunoGen Inc., (NASDAQ: IMGN) today announced that the U.S. Food and Drug Administration (FDA) has advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval for mirvetuximab soravtansine. Based on this guidance, the company will initiate SORAYA, a pivotal trial to evaluate mirvetuximab monotherapy in women with folate receptor alpha (FR)-high... More
